Work

Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.2527

Authors: Michael Timothy Tees, Sattva Swarup Neelapu, Parameswaran Hari, Sham Mailankody, David Bernard Miklos, Frederick Lundry Locke, Rajneesh Nath, Sacha Leandra Prashad, Xiangdong Zhou, Eren Demirhan, Srinand Ponnathapura Nandakumar, Dennis Fisher, Gregory Opiteck, Ena Wang

Institutions: Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Stanford Medicine, Stanford University, Allogene Therapeutics (United States)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3170501737

Cites:

Cited by: 13

Related to: 10